UBS Reaffirms PT and Rating on C3.AI
UBS analyst Radi Sultan reiterated on June 9, 2025, a ‘Neutral’ rating and $28 price target on C3.AI.
“We spent an hour with the company addressing key investor questions following the +21% post earnings move (now +13% since reporting).
Following our meeting, we feel incrementally better about what’s driving the decline in non-license sub revs but we still don’t have a great handle on the revs mix dynamic embedded in the FY26 guide.
If we assume flat license+pro serve revs from 4Q25, to hit the FY26 revs guide midpoint implies non-license sub revs averaging $61m/quarter (+15% vs the 4Q run-rate).
We still have questions given this has been down ~$4m q/q in each of the past two quarters and the pending step-down in Baker Hughes revs this year (unclear how much in non-license sub revs).
One potential explanation for the implied FY26 non-license sub revs ramp that we picked up was the revs lift opportunity from the pilots that have been completed but have not yet moved to a production contract.
There are ~150+ of these “latent” pilots that are still “active” but not currently generating any revs and the company noted the gap between pilot completion and the signing of a production contract can be “many months”.
On Federal, the $350m 4-year expansion of the Air Force contract is an intriguing y/y growth driver but our takeaway was that the associated revs in FY26 are likely going to be modest (we’d estimate ~$25m).
Net, given our lack of visibility into the revs mix dynamic and the stock trading at ~7x CY26 revs we prefer to remain on the sidelines in the near-term.”
The price target and rating on this page are the opinion of the issuing research firm and its analyst, not of Price Target. This page is published for informational purposes only and is not investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consider your own circumstances and consult a licensed financial adviser before making investment decisions.
This research note is reproduced verbatim from the issuing firm. Price Target never edits, paraphrases or alters analysts’ words — we only republish them in one place.


